You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

~ Buy the POLOXAMER 188 Drug Excipient Business Development Opportunity Report, 2024 PDF Report in the Report Store ~

Drugs Containing Excipient (Inactive Ingredient) POLOXAMER 188


✉ Email this page to a colleague

« Back to Dashboard


Branded drugs containing POLOXAMER 188 excipient, and estimated key patent expiration / generic entry dates

Generic drugs containing POLOXAMER 188 excipient

POLOXAMER 188 Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Poloxamer 188

Introduction

Poloxamer 188, a nonionic triblock copolymer, has been a staple in the pharmaceutical industry for its versatile applications, particularly as a surfactant and stabilizer. Here, we delve into the market dynamics and financial trajectory of Poloxamer 188, highlighting its current status, growth drivers, and future prospects.

Market Size and Growth Projections

The Poloxamer market, which includes Poloxamer 188, is experiencing significant growth. As of 2023, the global Poloxamer market was valued at USD 31.6 billion and is projected to reach USD 59.9 billion by 2033, growing at a CAGR of 6.6% from 2024 to 2033[2].

Key Applications of Poloxamer 188

Poloxamer 188 is widely used in various pharmaceutical and biotechnological applications:

Biomanufacturing and Cell Culture

Poloxamer 188 is crucial in biomanufacturing as a shear stress protectant for mammalian cell cultures. It ensures high cell viability and consistent biologic drug yields, making it a vital component in the production of biologics[1][4].

Drug Delivery Systems

In drug delivery, Poloxamer 188 enhances solubility and stability of pharmaceutical formulations. It is used in advanced drug delivery systems such as controlled-release matrices, liposomes, and polymer-based microparticles[1].

Parenteral Formulations

Poloxamer 188 is also used as a parenteral excipient, providing protection against shear stress and improving the stability of biological formulations[4].

Market Drivers

Several factors are driving the growth of the Poloxamer 188 market:

Increasing Demand in Biopharma

The biopharmaceutical industry's growth, driven by the increasing adoption of biologics and advanced drug delivery systems, is a significant driver. The need for high-quality excipients that can mitigate biological production risks and improve process yields is on the rise[1].

Technological Advancements

Advancements in manufacturing processes, such as those implemented by BASF to improve efficiency and yield, are reducing production costs and enhancing the quality of Poloxamer 188. This makes it more attractive to pharmaceutical and biotechnological companies[2].

Regulatory Compliance

Poloxamer 188 is generally recognized as safe (GRAS) by regulatory bodies like the FDA, which gives it a competitive advantage in markets requiring high safety and environmental standards[2].

Regional Dominance

The North American market holds a significant share of the Poloxamer market, valued at USD 13.0 billion, accounting for 46.3% of the global market. Europe is also a key region, expected to grow at a CAGR of 7.49% during the forecast period, driven by the expanding biotech and pharma industries[2][3].

Financial Trajectory

The financial trajectory of Poloxamer 188 is closely tied to the overall growth of the Poloxamer market:

Current Market Value

As part of the broader Poloxamer market, Poloxamer 188 contributes significantly to the current market value of USD 31.6 billion in 2023[2].

Future Projections

By 2033, the market is expected to reach USD 59.9 billion, indicating a robust growth trajectory. This growth is supported by the increasing demand for biopharmaceuticals and the expanding use of Poloxamer 188 in various applications[2].

Challenges and Opportunities

Despite the positive outlook, the market faces several challenges and opportunities:

Challenges

  • Stringent regulatory standards and the high cost of production are significant challenges. However, recent technological advancements aim to reduce costs and enhance efficiency[2].
  • Ensuring batch-to-batch consistency in cell culture performance is a critical challenge, which companies like Croda Pharma are addressing with products like Super Refined™ Poloxamer 188[4].

Opportunities

  • Emerging markets, especially in regions with growing pharmaceutical and cosmetic industries, offer new opportunities for Poloxamer 188. Expanding distribution channels and increasing market penetration in these regions can significantly boost sales[2].
  • The growing demand for multifunctional excipients that improve drug solubility, bioavailability, and stability presents a significant opportunity for Poloxamer 188[1].

Key Players

Several key players are driving the market for Poloxamer 188:

BASF

BASF is a leading player, focusing on producing high-purity Poloxamer 188 for pharmaceutical and biotechnological applications. Their efforts include collaborations to enhance quality and purity, which are crucial for improving drug solubility and stability[1][2].

Croda Pharma

Croda Pharma has developed Super Refined™ Poloxamer 188, optimized for mammalian cell culture and parenteral biological formulations. This product ensures batch-to-batch consistency and high purity standards, addressing a critical need in biomanufacturing[4].

Conclusion

Poloxamer 188 is poised for significant growth, driven by its versatile applications in biopharmaceuticals, advanced drug delivery systems, and compliance with stringent regulatory standards. The market's financial trajectory indicates a robust increase in value, with the global Poloxamer market expected to reach USD 59.9 billion by 2033. Addressing challenges such as batch-to-batch consistency and leveraging opportunities in emerging markets will be crucial for stakeholders to tap into the full potential of Poloxamer 188.

Key Takeaways

  • Market Growth: The Poloxamer market, including Poloxamer 188, is expected to grow from USD 31.6 billion in 2023 to USD 59.9 billion by 2033 at a CAGR of 6.6%.
  • Regional Dominance: North America holds a significant share, with Europe expected to grow at a CAGR of 7.49% during the forecast period.
  • Key Applications: Biomanufacturing, drug delivery systems, and parenteral formulations are key areas of use.
  • Market Drivers: Increasing demand in biopharma, technological advancements, and regulatory compliance are driving growth.
  • Challenges and Opportunities: Stringent regulations and high production costs are challenges, while emerging markets and the need for multifunctional excipients present opportunities.

FAQs

What is the current market value of the Poloxamer market?

The global Poloxamer market was valued at USD 31.6 billion in 2023[2].

What is the projected growth rate of the Poloxamer market?

The Poloxamer market is expected to grow at a CAGR of 6.6% from 2024 to 2033[2].

What are the primary applications of Poloxamer 188?

Poloxamer 188 is primarily used in biomanufacturing, drug delivery systems, and as a parenteral excipient[1][4].

Which regions are driving the growth of the Poloxamer market?

North America and Europe are significant regions driving the growth of the Poloxamer market[2][3].

What are the key challenges faced by the Poloxamer 188 market?

Stringent regulatory standards and the high cost of production are key challenges, along with ensuring batch-to-batch consistency in cell culture performance[2][4].

Sources

  1. Drug Development & Delivery: "New Excipients to Meet the Demands of a Challenging Industry"
  2. Market.us News: "Poloxamer Market set to surge, driven by biopharma growth"
  3. StraitsResearch: "Biopharmaceutical Excipients Market Size, Demand, Report to 2031"
  4. Croda Pharma: "Super Refined Poloxamer 188 - Croda Pharma"

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.